Tsumura : Supplementary Materials The Third Quarter of the Term Ending March 31, 2022

TSE.4540

Supplementary Materials

The Third Quarter of the Term Ending March 31, 2022

February 4, 2022

TSUMURA & CO.

Consolidated Statements of Income ・・・・・

1

・・・・・
Capital investments, R&D expenses, etc.	1
・・・・・
1
Growth rates of 129 prescription Kampo products
・・・・・
Product sales	2
・・・・・
Consolidated Balance Sheets	3
・・・・・
Consolidated Statements of Cash Flows	3
Quarterly data
4
4
5
5

Consolidated Statements of Cash Flows ・・・・・

Consolidated Statements of Income ・・・・・ Consolidated Balance Sheets ・・・・・

Product sales

・・・・・

※The 2020 results have been rearranged to the amount after applying the PPA adjustment and new accouting

Consolidated Statements of Income

(Million yen)

FY 3/2021 3Q cumulative	FY 3/2022 3Q cumulative	Year-on-year	Full-year forecast for FY 3/2022
Amount	% of sales	Amount	% of sales	Amount	%	Amount	% of sales	Year-on-year (Amount)	Year-on-year (%)
Net sales	88,444	100.0%	98,382	100.0%	9,938	11.2%	127,500	100.0%	11,086	9.5%
Domestic	84,579	95.6%	91,317	92.8%	6,737	8.0%	117,800	92.4%	7,746	7.0%
Overseas	3,864	4.4%	7,065	7.2%	3,200	82.8%	9,700	7.6%	3,339	52.5%
Cost of sales	41,693	47.1%	47,997	48.8%	6,304	15.1%	61,600	48.3%	5,650	10.1%
Gross profit on sales	46,750	52.9%	50,384	51.2%	3,634	7.8%	65,900	51.7%	5,435	9.0%
Selling, general and administrative expenses	29,514	33.4%	31,554	32.1%	2,040	6.9%	44,800	35.1%	3,718	9.1%
Operating profit	17,235	19.5%	18,829	19.1%	1,593	9.2%	21,100	16.5%	1,717	8.9%
Ordinary profit	17,811	20.1%	21,074	21.4%	3,262	18.3%	23,400	18.4%	2,533	12.1%
Profit attributable to owners of parent	13,226	15.0%	15,389	15.6%	2,162	16.4%	16,600	13.0%	1,267	8.3%

(Million yen)

Capital investments, R&D expenses, etc.

FY 3/2021 3Q cumulative	FY 3/2022 3Q cumulative	Year-on-year	Full-year forecast for FY 3/2022
Amount	% of sales	Amount	% of sales	Amount	%	Amount	% of sales	Year-on-year (Amount)	Year-on-year (%)
Capital investments	8,386	9.5%	6,716	6.8%	(1,670)	(19.9)%	14,000	11.0%	2,838	25.4%
R&D expenses	4,886	5.5%	5,193	5.3%	306	6.3%	7,300	5.7%	668	10.1%
Advertising cost	353	0.4%	481	0.5%	127	36.0%	1,000	0.8%	170	20.5%
Depreciation	5,975	6.8%	6,497	6.6%	521	8.7%	8,500	6.7%	289	3.5%
Personnel expenses	23,741	26.8%	24,145	24.5%	404	1.7%	32,700	25.6%	405	1.3%

Growth rates of 129 prescription Kampo products

FY 3/2015	FY 3/2016	FY 3/2017	FY 3/2018	FY 3/2019	FY 3/2020	FY 3/2021	FY 3/2022 1Q	FY 3/2022 2Q	FY 3/2022 3Q
Amount	2.4%	2.3%	1.9%	2.4%	2.7%	1.8%	1.1%	7.8%	7.7%	7.6%
Number of items with higher yen	sales 81	68	95	63	83	66	82	93	104	106

1

Product sales

(Million yen)

Rank	No.	Product Name	FY 3/2021 3Q	FY 3/2022 3Q	Year-on-year (Amount)	Year-on-year (%)
1	☆	100	Daikenchuto	7,125	7,334	209	2.9%
2	☆	54	Yokukansan	5,401	5,678	276	5.1%
3	G	41	Hochuekkito	5,328	5,655	327	6.1%
4	☆	43	Rikkunshito	5,168	5,548	380	7.4%
5	G	17	Goreisan	3,426	4,111	684	20.0%
6	G	24	Kamishoyosan	3,350	3,752	401	12.0%
7	G	68	Shakuyakukanzoto	3,521	3,692	171	4.9%
8	☆	107	Goshajinkigan	2,479	2,687	207	8.4%
9	114	Saireito	2,387	2,559	171	7.2%
10	G	29	Bakumondoto	2,417	2,455	37	1.6%
23	☆	14	Hangeshashinto	973	1,052	79	8.1%
Total of "Drug Fostering" Program formulations	21,148	22,301	1,153	5.5%
Total of Growing formulations	18,044	19,666	1,622	9.0%
Total of 129 prescription Kampo products	81,127	87,293	6,166	7.6%

☆ ："Drug Fostering" Program formulations

G ：Growing formulations

Consolidated Balance Sheets

(Million yen)

As of March 31 2021	As of December 31, 2021	Increase / decrease
Total assets	319,063	338,432	19,368
Current assets	204,273	221,541	17,268
Liquid assets	109,934	121,193	11,258
Inventories	80,755	87,217	6,462
Non-current assets	114,789	116,890	2,100
Property, plant and equipment	84,176	86,548	2,371
Total liabilities	85,894	88,946	3,052
Current liabilities	48,380	41,986	(6,394)
Non-current liabilities	37,513	46,960	9,446
Total net assets	233,169	249,485	16,316

Consolidated Statements of Cash Flows

(Million yen)

FY 3/2021 3Q	FY 3/2022 3Q	Year-on-year
Cash flows from operating activities	12,706	17,815	5,108
Cash flows from investing activities	(4,975)	(7,510)	(2,534)
Cash flows from financing activities	(9,708)	(5,192)	4,515
Cash and cash equivalents at the end of the quarter	59,051	67,070	8,019